Create a free research account to view current pricing and place an order.
How does ARA-290 work in research models?
ARA-290 is an innate repair receptor agonist peptide derived from the tissue-protective domain of erythropoietin. It is researched for neuropathy, inflammatory modulation, endothelial protection, and tissue-protective signaling without erythropoietic activity.
What is the half-life of ARA-290?
Half-life: Short acting.
Human pharmacokinetics are not standardized. Treat exposure as short acting unless compound-specific data or formal formulation labeling indicates otherwise.
Research dosing reference
2-4 mg daily in neuropathy/tissue-protective research contexts.
Dose interpretation (U-100 units)
| Target dose | U-100 units |
|---|---|
| 2 mg | 40 units |
| 4 mg | 80 units |
Units are concentration-specific - confirm against your actual reconstitution volume.
How is ARA-290 reconstituted?
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 10 mg | 2 mL BAC Water | 0.050 mg/unit |
Injection timing
Often administered daily; consistency is preferred for neuropathy-oriented protocols.
Beginner escalation
Begin at the lower end and evaluate nerve-symptom response and injection tolerance before increasing.
Side-effect mitigation
Monitor headache, fatigue, injection irritation, flushing, or symptom changes.
Stack compatibility
Pairs with regenerative and mitochondrial pathways; avoid adding multiple neuro/immune-active agents simultaneously.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
Acute repair protocols are commonly structured as 2-6 week focused blocks, then reassess pain, mobility, inflammatory response, and tissue objective. Maintenance, if used, should be lower-frequency and objective-driven. Growth Hormone Axis
Frequently asked questions
What is ARA-290 and how is it studied?
ARA-290 is an innate repair receptor agonist peptide derived from the tissue-protective domain of erythropoietin. It is researched for neuropathy, inflammatory modulation, endothelial protection, and tissue-protective signaling without erythropoietic activity. ARA-290 is catalogued in the Recovery / Regenerative group of this reference and is studied in laboratory and in-vitro models only.
What is known about the half-life of ARA-290?
Reference half-life for ARA-290: short acting. Human pharmacokinetics are not standardized. Treat exposure as short acting unless compound-specific data or formal formulation labeling indicates otherwise. Published pharmacokinetic figures come from research and clinical-literature contexts and are listed here as reference values for laboratory work only, not as guidance for any person or animal.
How is ARA-290 stored?
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically. Lyophilized research peptides are generally kept cold, dry, and away from light, and reconstituted solutions are labeled with concentration and date. Follow the storage conditions documented for the specific lot you receive.
How is ARA-290 reconstituted for laboratory work?
The reference reconstitution for the 10 mg vial is 2 mL BAC Water, which gives a concentration of about 5 mg/mL. Concentration equals peptide mass divided by diluent volume, so adding more liquid lowers the concentration. Add diluent slowly down the vial wall, swirl rather than shake, and confirm the arithmetic before preparing any research solution.
Is ARA-290 FDA approved?
No. The research-grade ARA-290 described here is an investigational, research-use-only material and is not an FDA-approved drug product. Where an approved pharmaceutical form of a compound exists, it is a separate prescription product. This reference is not medical advice, and the material is not for human or animal consumption.
All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration